Kalpit Patel
Stock Analyst at B. Riley Securities
(0.88)
# 3,764
Out of 4,877 analysts
55
Total ratings
33.33%
Success rate
-13.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Upgrades: Buy | $38 → $60 | $43.66 | +37.43% | 3 | Jun 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $6.95 | +101.58% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $21.78 | +69.92% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $18.71 | +28.27% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.41 | +149.11% | 3 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $4.15 | +116.87% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $4.70 | +112.77% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.33 | +426.32% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $6.90 | +479.71% | 2 | Sep 20, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $0.33 | +809.64% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $13.98 | +43.06% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $1.90 | +1,478.95% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $7.15 | -16.08% | 5 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $9.37 | +284.41% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $2.09 | +4,206.22% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.13 | +1,492.92% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.92 | +160.42% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $7.47 | +1,238.69% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $12.93 | +480.05% | 2 | Sep 3, 2021 |
Kymera Therapeutics
Jun 3, 2025
Upgrades: Buy
Price Target: $38 → $60
Current: $43.66
Upside: +37.43%
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $6.95
Upside: +101.58%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $21.78
Upside: +69.92%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $18.71
Upside: +28.27%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.41
Upside: +149.11%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $4.15
Upside: +116.87%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.70
Upside: +112.77%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.33
Upside: +426.32%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $6.90
Upside: +479.71%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.33
Upside: +809.64%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $13.98
Upside: +43.06%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $1.90
Upside: +1,478.95%
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $7.15
Upside: -16.08%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $9.37
Upside: +284.41%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $2.09
Upside: +4,206.22%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.13
Upside: +1,492.92%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.92
Upside: +160.42%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $7.47
Upside: +1,238.69%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $12.93
Upside: +480.05%